Results 81 to 90 of about 78,184 (307)

Comparative CNS Pharmacology of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis

bioRxiv
Tolebrutinib is a covalent BTK inhibitor designed and selected for potency and CNS exposure to optimize impact on BTK-dependent signaling in CNS-resident cells.
Timothy J. Turner, Priscilla Brun, Ross Gruber, D. Ofengeim   +3 more
semanticscholar   +1 more source

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

Blood, 2020
Treon et al provide early clinical data supporting a theoretical rationale for continuing ibrutinib in patients receiving the drug during COVID-19 illness.
S. Treon, J. Castillo, A. Skarbnik, J. Soumerai, I. Ghobrial, M. Guerrera, K. Meid, Guang Yang   +7 more
semanticscholar   +1 more source

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

Blood Advances, 2021
Key Points Patients with CLL sequentially resistant to both BCL2 and covalent BTK inhibition have a poor prognosis and represent an area of unmet need.
T. Lew, V. Lin, E. Cliff, P. Blombery, E. Thompson, S. Handunnetti, D. Westerman, B. Kuss, C. Tam, D. Huang, J. Seymour, A. Roberts, M. Anderson   +12 more
semanticscholar   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

Arthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Bruton's Tyrosine Kinase (BTK) and Vav1 contribute to Dectin1-dependent phagocytosis of Candida albicans in macrophages.

PLoS Pathogens, 2013
Phagocytosis of the opportunistic fungal pathogen Candida albicans by cells of the innate immune system is vital to prevent infection. Dectin-1 is the major phagocytic receptor involved in anti-fungal immunity. We identify two new interacting proteins of
Karin Strijbis, Fikadu G Tafesse, Gregory D Fairn, Martin D Witte, Stephanie K Dougan, Nicki Watson, Eric Spooner, Alexandre Esteban, Valmik K Vyas, Gerald R Fink, Sergio Grinstein, Hidde L Ploegh   +11 more
doaj   +1 more source

Immunomodulating effects of antitumor drugs Bruton tyrosine kinase inhibitors and the possibility of their use in allergic and infectious diseases

Медицинская иммунология, 2023
Bruton's tyrosine kinase (BTK) inhibitors represent a class of drugs that have demonstrated their efficacy and safety in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphomas who were considered refractory to any previously used type of ...
Yu. S. Torshina, N. B. Serebryanaya, T. V. Glazanova, M. A. Mikhalyova, S. V. Voloshin   +4 more
doaj   +1 more source

BTK: sensing pathogenic nucleic acids

Oncotarget, 2015
We are under constant threats from pathogens. A failure to initiate an appropriate immune response will lead to an immunocompromised state. Our innate immune system could sense foreign nucleic acids from parasites, viruses, fungi and bacteria. This is achieved through pattern recognition receptors (PRRs) on innate cells such as macrophages that ...
Koon-Guan, Lee, Kong-Peng, Lam
openaire   +2 more sources

Integrin Signaling Shaping BTK-Inhibitor Resistance

Cells, 2022
Integrins are adhesion molecules that function as anchors in retaining tumor cells in supportive tissues and facilitating metastasis. Beta1 integrins are known to contribute to cell adhesion-mediated drug resistance in cancer. Very late antigen-4 (VLA-4), a CD49d/CD29 heterodimer, is a beta1 integrin implicated in therapy resistance in both solid ...
Laura Polcik, Svenja Dannewitz Prosseda, Federico Pozzo, Antonella Zucchetto, Valter Gattei, Tanja Nicole Hartmann   +5 more
openaire   +4 more sources

Interleukin‐5, Eosinophils, and Interleukin‐5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis

Arthritis &Rheumatology, EarlyView.
Interlukin‐5 (IL‐5) plays a crucial role in the pathogenesis of eosinophilic granulomatosis with polyangiitis (EGPA) by promoting eosinophil differentiation, activation, and survival. We present here a typical case of EGPA in which treatment with IL‐5 pathway inhibitors is prescribed, showing to be beneficial for the patient.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

Előszó

Elpis, 2020
Jelen számunkat Steiger Kornél 75. születésnapja alkalmából állítottuk össze. Az ünnepeltet Mogyoródi Emese később a mi nevünkben is köszönti, ezért itt a szerkesztési elveket emelnénk ki.
Nikoletta Hendrik, Kosztasz Rosta
doaj